Provided by Tiger Fintech (Singapore) Pte. Ltd.

OCUMENSION-B

8.760
+0.1401.62%
Volume:1.17M
Turnover:10.15M
Market Cap:7.14B
PE:-20.39
High:8.850
Open:8.660
Low:8.510
Close:8.620
52wk High:12.230
52wk Low:3.620
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:0.97
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.430
ROE:-7.76%
ROA:-5.07%
PB:1.78
PE(LYR):-20.39
PS:11.99

Loading ...

ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development

Stock News
·
Yesterday

Pharmaceutical Sector Boosted as FDA Leadership Change Restores Market Confidence, Drug Stocks Hit Record Highs

Stock News
·
Yesterday

ASCLETIS-B (01672): Monthly-Dose Next-Gen Amylin Receptor Agonist ASC36 and GLP-1R/GIPR Dual-Target Agonist ASC35 Combo Advances to Clinical Development

Stock News
·
Yesterday

LAEKNA-B (02105) Enters Exclusive Licensing Agreement with Qilu Pharma for LAE 002 (Afuresertib) in China

Stock News
·
Nov 12

HK Stock Movement | ASCLETIS-B (01672) Surges Over 7% in Late Trading as ASC36 Enters Clinical Development Phase, IND Application to Be Submitted in Q2 Next Year

Stock News
·
Nov 11

Ionis Pharmaceuticals Pre-Market Shares Plunge Over 13%, Currently at $63.63

Deep News
·
Nov 10

Tiansheng Pharmaceutical Group Co.,Ltd. (002872) Penalized, Shareholder Compensation Claims Expected

Deep News
·
Nov 10

Weijian Pharma Submits Listing Application to HKEX, Leads in Commercialized Innovative Kidney Disease Drugs Among Chinese Pharma Firms

Stock News
·
Nov 10

Novartis AG (NVS.US) Gains Dual Indication Approval for First Radioligand Therapy Drug Pluvicto®

Stock News
·
Nov 06

MSCI Global Small Cap Index Rebalance: Ascletis-B (01672), Chabaidao (02555) Among 22 Stocks Added

Stock News
·
Nov 06

ASCLETIS-B (01672) Repurchased 100,000 Shares for HK$924,000 on November 5

Stock News
·
Nov 05

ASCLETIS-B (01672) Presents Full Analysis of ASC30 Oral Tablet Ib Study, ASC30 Injection Ib Study, and ASC31/ASC47 Combination Preclinical Research at ObesityWeek® 2025

Stock News
·
Nov 05

Surge in Demand for Anti-Flu Drugs: Market Competition Intensifies

Deep News
·
Nov 05

Sinolink Securities: Pharmaceutical Sector Shows Divergence in Q3 2025, Accelerated Growth in Innovative Drugs

Stock News
·
Nov 03

Lupeng Pharmaceuticals Submits IPO Application to HKEX, Core Product LP-168 is the World's First and Only Dual "Covalent and Non-Covalent" BTK Inhibitor

Stock News
·
Nov 02

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$1.93 Million on October 31

Stock News
·
Oct 31

Hong Kong Stocks Movement | ASCLETIS-B (01672) Rises Over 4% as Subcutaneous Amylin Receptor Agonist ASC36 Enters Clinical Development

Stock News
·
Oct 31

U.S. Stock Movement | Moderna (MRNA.US) Surges Over 9% Amid Acquisition Talks with Major Pharma

Stock News
·
Oct 30

ASCLETIS-B (01672) Selects Best-in-Class Monthly Subcutaneous Amylin Receptor Agonist ASC36 for Clinical Development

Stock News
·
Oct 30

China's 11th National Drug Procurement Bidding Concludes: 55 Drugs in Fierce Price Competition as New Rules Reshape Industry Logic

Stock News
·
Oct 29